CI (The Cigna Group)
Insider Trading Activity
Every open-market purchase and sale reported by CI officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-03 | Brian C Evanko | See Remarks | A | — | — |
| 2026-09-02 | George Kurian | Director | A | — | — |
| 2026-08-20 | Nicole S Jones | See Remarks | Sell | — | — |
| 2026-08-20 | Bryan Holgerson | See Remarks | A | — | — |
| 2026-08-06 | Nicole S Jones | See Remarks | MIXED | — | — |
| 2026-08-06 | Nicole S Jones | See Remarks | MIXED | — | — |
| 2026-06-16 | Jamie G Kates | Chief Accounting Officer | MIXED | — | — |
| 2026-06-03 | Durga Prasad Koka | EVP, Global CIO | F | — | — |
| 2026-06-02 | George Kurian | Director | A | — | — |
| 2026-05-14 | David Cordani | Chairman & CEO | MIXED | — | — |
| 2026-04-24 | ERIC C WISEMAN | Director | A | — | — |
| 2026-04-24 | Philip Ozuah | Director | A | — | — |
| 2026-04-24 | Michael J Hennigan | Director | A | — | — |
| 2026-04-24 | Kimberly A. Ross | Director | A | — | — |
| 2026-04-24 | George Kurian | Director | A | — | — |
| 2026-04-24 | KATHLEEN M MAZZARELLA | Director | A | — | — |
| 2026-04-24 | DONNA F ZARCONE | Director | A | — | — |
| 2026-04-24 | Neesha Hathi | Director | A | — | — |
| 2026-04-24 | Mark B. McClellan | Director | A | — | — |
| 2026-04-24 | ERIC J FOSS | Director | A | — | — |
| 2026-03-03 | George Kurian | Director | A | — | — |
| 2026-03-03 | David Cordani | Chairman & CEO | MIXED | — | — |
| 2026-03-03 | ANN M DENNISON | EVP, CFO | MIXED | — | — |
| 2026-03-03 | Brian C Evanko | See Remarks | MIXED | — | — |
| 2026-03-03 | Nicole S Jones | See Remarks | MIXED | — | — |
| 2026-03-03 | Everett Neville | See Remarks | MIXED | — | — |
| 2026-03-03 | Durga Prasad Koka | EVP, Global CIO | MIXED | — | — |
| 2026-03-03 | Jamie G Kates | Chief Accounting Officer | MIXED | — | — |
| 2025-12-02 | George Kurian | Director | A | — | — |
| 2025-11-03 | David Cordani | Chairman & CEO | Buy | — | — |
| 2025-10-07 | Brian C Evanko | See Remarks | MIXED | — | — |
| 2025-09-03 | DAVID J BRAILER | EVP & Chief Health Officer | F | — | — |
| 2025-09-03 | George Kurian | Director | A | — | — |
| 2025-08-19 | Nicole S Jones | See Remarks | MIXED | — | — |
| 2025-06-04 | Michael J Hennigan | Director | A | — | — |
| 2025-06-03 | George Kurian | Director | A | — | — |
| 2025-04-25 | ERIC J FOSS | Director | A | — | — |
| 2025-04-25 | Elder Granger | Director | A | — | — |
| 2025-04-25 | Neesha Hathi | Director | A | — | — |
| 2025-04-25 | KATHLEEN M MAZZARELLA | Director | A | — | — |
| 2025-04-25 | Mark B. McClellan | Director | A | — | — |
| 2025-04-25 | Philip Ozuah | Director | A | — | — |
| 2025-04-25 | Kimberly A. Ross | Director | A | — | — |
| 2025-04-25 | George Kurian | Director | A | — | — |
| 2025-04-25 | ERIC C WISEMAN | Director | A | — | — |
| 2025-04-25 | DONNA F ZARCONE | Director | A | — | — |
| 2025-03-17 | Elder Granger | Director | MIXED | — | — |
| 2025-03-11 | Noelle K Eder | See Remarks | Sell | — | — |
| 2025-03-04 | Nicole S Jones | See Remarks | MIXED | — | — |
| 2025-03-04 | David Cordani | Chairman & CEO | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chairman & CEO | 1,782,682 | — |
| — | Chairman & CEO | 307,285 | — |
| — | President, HealthSpring | 253,232 | — |
| — | EVP, CFO | 165,552 | — |
| — | President, International | 96,391 | — |
| — | Pres. CIGNA International | 83,789 | — |
| — | EVP, Chief Financial Officer | 77,235 | — |
| — | See Remarks | 70,504 | — |
| — | EVP, General Counsel | 68,588 | — |
| — | See Remarks | 66,644 | — |
| — | CEO Evernorth | 61,267 | — |
| — | EVP & Chief Admin Officer | 54,975 | — |
| — | EVP, Chief Information Officer | 49,634 | — |
| — | Director | 48,839 | — |
| — | Pres., International Health | 47,015 | — |
| — | Pres, Government and Solutions | 43,488 | — |
| — | EVP & Chief Financial Officer | 43,295 | — |
| — | Special Advisor | 41,028 | — |
| — | Director | 38,453 | — |
| — | Director | 36,696 | — |
| — | Pres. Grp Ins Dntl Vis & Pharm | 32,770 | — |
| — | EVP Service and IT & CIO | 32,124 | — |
| — | EVP, Chief Clinical Officer | 31,377 | — |
| — | Pres. Global Employer Segment | 30,561 | — |
| — | Director | 29,797 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CI quote page; the site-wide leaderboard is on the insider transactions hub.